This company belongs to the group of diagnostic services companies in India offering pathology, clinical laboratory, and diagnostic test services through their laboratories and sampling centers.
The shares of Dr Lal PathLabs are currently trading at Rs. 1937.80, down by 1.24%. The company has a market capitalization of RS. 32,443.50 crore. The stock’s 52 week high is Rs. 2,035.00 and its 52 week low is Rs. 1,272.00. In the past 6 months the stock has delivered a return of 43.83%.
What’s The News
Approvals have been received from Dr Lal PathLabs Limited for acquisition of 70% equity shares in SN Genelab Private Limited (SN Gene). This transaction has been approved by the company’s Board of Directors on September 24, 2026 and is due to be completed by November 30, 2026..
This deal will entail a total cash consideration of up to Rs. 168 crore for the 70% stake and a performance linked earn out amount of up to Rs. 31.5 crore, which means the deal has a maximum potential of Rs. 199.5 crore if the earn out amount is fully considered.
After the completion of the deal, SN Genelab will become a wholly owned subsidiary of Dr Lal PathLabs Limited. The firm claims that the objective behind this acquisition is to add value to its genomics capabilities and advanced diagnostics offerings.
About SN Genelab
SN Genelab Private Limited was established on 16 December 2013 in the Indian state of Gujarat. This company belongs to the diagnostics and genomics industry and is expected to provide genomics services to Dr Lal PathLabs after the proposed acquisition.
The SN Gene has witnessed continuous improvement in its turnover during the past three financial years. Its turnover has grown from Rs. 43.27 crore in FY24 to Rs. 53.36 crore in FY25 before growing to Rs. 57.96 crore in FY26. Dr Lal PathLabs is willing to purchase 70% equity in the company in return for up to Rs. 168 crore in primary consideration, along with earn-out consideration of up to Rs. 31.5 crore. Thus, the total consideration may go up to Rs. 199.5 crore.
The acquisition is anticipated to be finalized before the end of November 30, 2026, subject to the satisfaction of certain conditions precedent. On successful finalization, it is anticipated that SN Genelab will become a subsidiary of Dr Lal PathLabs, enhancing its footprint in the field of genomics and molecular diagnostics.
Strategic Significance
The acquisition will expand Dr Lal PathLabs’ capabilities in genomics and advanced diagnostics, an area where specialised testing and technology are becoming increasingly important within the diagnostics industry.
By acquiring a majority stake in SN Gene, Dr Lal PathLabs will gain control over an existing genomics-focused business while adding its capabilities to the company’s broader diagnostic network. The transaction also provides an avenue for Dr Lal PathLabs to expand its advanced testing portfolio beyond conventional diagnostic services.
The company has stated that the transaction does not qualify as a related-party transaction and does not require any governmental or regulatory approvals.
Investor Perspective
The proposed acquisition gives Dr Lal PathLabs a majority position in a genomics-focused diagnostics company and could broaden its advanced diagnostic service portfolio. SN Gene’s turnover has also increased from Rs. 43.27 crore in FY24 to Rs. 57.96 crore in FY26, although the financial contribution to Dr Lal PathLabs will become clearer only after the transaction is completed and the business is integrated.
For investors, the key developments to monitor will be the completion of the acquisition, integration of SN Gene, growth in genomics testing, revenue contribution, margins and the eventual payment of the performance-linked earn-out.
Company Overview
Dr. Lal PathLabs is one of India’s established diagnostic services providers, offering pathology, clinical laboratory and diagnostic testing services through its network of laboratories and collection centres. The company has been expanding its portfolio toward specialised and advanced diagnostic services as part of its broader strategy to strengthen its presence across India’s growing healthcare and diagnostics market.